Tigecycline Safety, Contraindications, and Evidence‑Based Use in Wound Infections

1. Mortality Signal in Clinical Trials

In phase 3 and 4 trials of complicated skin and soft‑tissue infections, intra‑abdominal infections, diabetic foot infections, and nosocomial pneumonia, patients receiving tigecycline experienced numerically higher all‑cause mortality compared with comparator antibiotics. Evidence level: moderate (meta‑analysis of randomized trials). 1, 2, 3, 4

Hypersensitivity to tigecycline or any tetracycline class is a contraindication. Evidence level: strong (regulatory labeling). 1, 2, 3, 4
Children < 8 years are contraindicated because of the risk of permanent tooth discoloration. Evidence level: strong (regulatory labeling). 1, 2, 3, 4
Pregnancy and breastfeeding are contraindicated owing to fetal toxicity demonstrated in animal studies. Evidence level: strong (regulatory labeling). 1, 2, 3, 4

No routine dose adjustment is required for patients with renal impairment, although clinicians should exercise caution. Evidence level: low (expert opinion). 1, 2

Gastro‑intestinal: nausea, vomiting, diarrhea, and abdominal pain are very common. Evidence level: strong (clinical trial safety data). 1, 2, 3, 4
Hepatic: elevations in liver‑function tests occur frequently. Evidence level: strong. 1, 2, 3, 4
Hematologic: prolonged activated partial thromboplastin time (aPTT) and prothrombin time (PT) have been reported. Evidence level: strong. 1, 2, 3, 4
Dermatologic: pruritus and rash are common. Evidence level: strong. 1, 2, 3, 4

Serum tigecycline level monitoring is not currently available in the United Kingdom and is not routinely performed elsewhere. Evidence level: low (practical limitation). 1, 2, 3, 4

For complicated skin and soft‑tissue infections caused by MDR organisms with a tigecycline minimum inhibitory concentration (MIC) ≤ 1 mg/L, the standard regimen (100 mg IV loading dose, then 50 mg IV every 12 h) may be used. Evidence level: moderate (clinical guideline). 5, 6
When tigecycline is employed for MDR pathogens, combination therapy with another active antimicrobial is recommended to mitigate uncertainties about monotherapy efficacy. Evidence level: moderate (guideline recommendation). 5

The 2022 ESCMID guidelines strongly advise against using tigecycline for infections caused by third‑generation‑cephalosporin‑resistant Enterobacterales when alternative agents are available, emphasizing antimicrobial stewardship. Evidence level: strong (guideline). 7

First‑line agents (e.g., β‑lactams, vancomycin) are appropriate and effective; tigecycline should be reserved. Evidence level: strong (guideline). 7
Bacteremia is a contraindication because tigecycline achieves low serum concentrations, limiting efficacy. Evidence level: moderate (guideline). 5, 6
Pregnant, breastfeeding, or children < 8 years (see contraindications above). Evidence level: strong. 1, 2, 3, 4